Abstract：Objective To observe the effectiveness and safety of high dose atorvastatin in the treatment of acute ischemic non-minor stroke.Methods A total of 125 patients within 24 hours of acute ischemic stroke onset whose NIHSS scores were less than 4 were randomly divided into the high dose group(62 patients) and the conventional dose group(63 patients).The high dose group and the conventional dose group received atorvastatin 40 mg and atorvastatin 20 mg before bedtime respectively.TCH, TG, HDL-C, LDL-C, liver test, creatine kinase, NIHSS score, mRS, and the number of symptomatic intracranial hemorrhage patients were observed in both groups before and after two weeks of treatment, while the rate of cerebral infarction recurrence was observed after three months of treatment.Results After treatment, NIHSS scores of the two groups were decreased, especially in the high dose group, so there was significant difference (P<0.05).mRS of the two groups was also decreased, especially in the high dose group, and the difference was significant(P<0.05).There was no significant difference in the incidence of cerebral infarction between the two groups.TCH, TG and LDL-C of the two groups were decreased after two weeks of treatment, especially so in the high dose group, so there was significant difference (P<0.05).Between the two groups, there was no significant difference in the rate of liver test abnormalities, creatine kinase abnormalities or symptomatic intracranial hemorrhage.Conclusions A high dose of atorvastatin therapy for acute ischemic non-minor stroke can improve blood lipid levels and neurological function, and no obvious adverse reactions occur.
Flint A C, Kamel H, Navi B B.Statin use during ischemic stroke hospitalization is strongly associated with improved poststroke survival[J].Stroke, 2012,43(1):147-154.
Rao N M, Levine S R, Gornbein J A, et al.Defining clinically relevant cerebral hemorrhage after thrombolytic therapy for stroke: analysis of the National Institute of Neurological Disorders and Stroke tissue-type plasminogen activator trials[J].Stroke, 2014, 45(9): 2728-2733.
[6]
Wang L, Zhang X, Liu L, et al.Atorvastatin protects rat brains against permanent focal ischemia and downregulates HMGB1,HMGB1 receptors (RAGE and TLR4), NF-kappaB expression[J].NeurosciLett, 2010, 471(3):152-156.
[7]
Wang N,Tall A R.cholesterol in platelet biogenesis and activation[J].Blood, 2016, 127(16):1949-1953.
[8]
Al-Khaled M, Matthis C, Eggers J.Statin treatment in patients with acute ischemic stroke[J].Int J Stroke, 2014, 9(5): 597-601.
[9]
Tsivgoulis G, Katsanos A H, Sharma V K, et al.Statin pretreatment is associated with better outcomes in large artery atherosclerotic stroke[J].Neurology, 2016, 86(12): 1103-1111.
[10]
Ridker P M,Danielson E,Fonseca F A,et al.Rosuvastatin to prevent vascular events in men and women with elevated creactive protein [J].N Engl J Med, 2008, 359(21): 2195-2207.
[11]
Ambapkar S, Shetty N, Dwivedy A,et al.Statin-induced rhabdomyolysis in patient with renal failure and underlying undiagnosed hypothyroidism[J].Indian J Critical Care Med, 2016, 20(5): 305-307.
[12]
Kim B J, Lee S H, Ryu W S, et al.Low level of low-density lipoprotein cholesterol increases hemorrhagic transformation in large artery atherothrombosis but not in cardioembolism[J].Stroke, 2009, 40(5): 1627-1632.
2018, Vol. 29 
